129177-21-5

Basic information

• Product Name: 5-CHLORO-3-(4-CHLOROPHENYL)[1,2,4]TRIAZOLO[4,3-C]QUINAZOLINE
• Synonyms: 5-CHLORO-3-(4-CHLOROPHENYL)[1,2,4]TRIAZOLO[4,3-C]QUINAZOLINE
• CAS NO: 129177-21-5
• Molecular Formula: C₁₅H₈Cl₂N₄
• Molecular Weight: 315.16
• Mol File: 129177-21-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-CHLORO-3-(4-CHLOROPHENYL)[1,2,4]TRIAZOLO[4,3-C]QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-(4-CHLOROPHENYL)[1,2,4]TRIAZOLO[4,3-C]QUINAZOLINE(129177-21-5)
• EPA Substance Registry System: 5-CHLORO-3-(4-CHLOROPHENYL)[1,2,4]TRIAZOLO[4,3-C]QUINAZOLINE(129177-21-5)

Safety Data

• Hazardous Substances Data: 129177-21-5(Hazardous Substances Data)

Upstream product

• 87610-94-4 2‐chloro‐4‐hydrazinylquinazoline 
• 129177-33-9 3-(4-Chlorophenyl)-5,6-dihydro-5-oxo-1,2,4-triazolo<4,3-c>quinazoline 
• 607-68-1 2,4-dichloroquinazoline 
• 104-88-1 4-chlorobenzaldehyde 
• 129177-12-4 1-(4-Chlorobenzylidene)-2-(2-chloro-4-quinazolyl)hydrazine 

Downstream Products

• 129177-25-9 3-(4-Chlorophenyl)-5-(4-morpholinyl)-1,2,4-triazolo<4,3-c>quinazoline 
• 129177-28-2 3-(4-Chloro-phenyl)-5-ethoxy-[1,2,4]triazolo[4,3-c]quinazoline 

Relevant articles and documents

Compound and application thereof

The invention relates to a compound and application thereof. When the compound of 1 the present invention is used as an electron transport layer material in an organic electroluminescent device, electron injection and transfer efficiency in the device can

1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity

Targeting PCAF with small inhibitor molecules has emerged as a potential therapeutic strategy for the treatment of cancer. Recently, L-45 was identified as a potent triazolophthalazine inhibitor of the PCAF bromodomain. Here, we report the bioisosteric modification of the triazolophthalazine ring system of L-45 to its bioisosteric triazoloquinazoline while maintaining other essential structural fragments for effective binding with the binding site of PCAF. Consequently, a set of sixteen triazoloquinazoline derivatives were designed, synthesized, and investigated for their anticancer activity against four human cancer cell lines. Five derivatives demonstrated comparable cytotoxic activity with that of doxorubicin as a reference anticancer drug. Among them, compound23showed the most potent activity with IC50values of 6.12, 4.08, 7.17, and 6.42 μM against HePG2, MCF-7, PC3, and HCT-116, respectively. Also, compound21exhibited comparable cytotoxic effects with that of doxorubicin against the selected cancer cell lines with IC50values in the range of 7.41-9.58 μM. Molecular docking and pharmacokinetic studies were additionally performed to rationalize the binding affinities of the newly designed triazoloquinazolines toward the active site of histone acetyltransferase PCAF and to evaluate the druggability of new compounds. The results of these studies suggested that PCAF binding could be the mechanism of action of these derivatives.

Organic electroluminescent material and organic electroluminescent device

The present invention relates to a compound, which has a structural formula represented by a formula (1), L is a single bond, a C6-C30 arylene or C3-C30 heteroarylene, m is an integer of 1-4, R and R are respectively and independently H, C6-C30 aryl or C3-C30 heteroaryl, Ar has a structure defined in the specification, X-X are C, CR or N, at least one of X is N, R is H or C3-C30 aryl or heteroaryl having 0-3 hetero atoms, and when a plurality of R are present, the plurality of the R are the same or different from each other. The invention further relates to an organic electroluminescent device containing the compound.